Trials / Completed
CompletedNCT05256654
A Study of LY3561774 in Participants With Mixed Dyslipidemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3561774 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2022-07-20
- Primary completion
- 2024-03-04
- Completion
- 2024-05-23
- First posted
- 2022-02-25
- Last updated
- 2025-03-17
- Results posted
- 2025-03-17
Locations
41 sites across 7 countries: United States, Argentina, Canada, Japan, Mexico, Poland, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05256654. Inclusion in this directory is not an endorsement.